⌕
Scinai Immunotherapeutics · SCNI · Nasdaq
Tenet 21 · Weak
Compare
$1.55+323.14%At closeTenet 21 · Weak
$1.55+1.19 (+323.14%)
At close: Nov 19, 2026, 4:00 PM ET· Nasdaq · USD

Scinai Immunotherapeutics (SCNI) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue history is too short to read a growth trend, net margin −633.6%. Worth your attention in FY25: Share count (+1554.2%) and Capex step-up ($24.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($K)▲99.2%
1,311.0
FY21→FY25CAGR —
Net income ($K)—
−8,307.0
FY21→FY25CAGR —
Free cash flow ($K)▲4.6%
−6,055.0
capex stepped upCAGR —
Diluted EPS—
0.00
no value for 2 of 5 yearsCAGR —
What the receipts whisper · what a headline number hides
Share count
+1554.2%

0.6bn → 9.3bn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$24.0K

▲100% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($K)1311.0Revenue−3963.0COGS−2652.0Gross profit−2369.0R&D−2521.0SG&A−7542.0Op income−765.0Tax & other−8307.0Net income

-634¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
7305483651830%FY21FY25

Net margin -633.6% is below the sector median.

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 7.11, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—1,311.0658.00.00.00.0▲99.2%—
Cost of revenue
—3,963.01,238.00.00.00.0▲220.1%—
Gross profit
—−2,652.0−580.00.00.00.0▼357.2%—
Research & development
6,597.02,369.05,532.05,210.05,765.03,249.0▼57.2%−7.6%
Selling, general & admin
5,035.02,521.02,526.04,505.05,296.07,625.0▼0.2%−24.2%
Total operating expenses
11,632.04,890.08,058.09,715.011,061.010,874.0▼39.3%−18.1%
Operating incomefeeds ROC rank
−11,632.0−7,542.0−8,638.0−9,706.0−11,061.0−10,874.0▲12.7%—
Other income, net
4,796.0−765.013,434.03,215.05,265.02,668.0——
Pretax income
−6,836.0−8,307.04,796.0−6,491.0−5,796.0−8,206.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−6,836.0−8,307.04,796.0−6,500.0−5,796.0−8,206.0——
Per share
Diluted EPSbuyback-sensitive
—0.000.00——−0.02b——
Diluted shares (bn)
—9.343.23——0.56▲189.6%—
Margins
Gross margin0th pct in Healthcare
—−202.3%−88.1%———▼114.1pp—
Operating margin
—−575.3%−1312.8%———▲737.5pp—
Net margin13th pct in Healthcare
—−633.6%728.9%———▼1362.5pp—
† TTM = trailing four quarters through 2023-03-31.b Basic EPS. The company's diluted figure is not in our data feed for this period; its reported basic EPS agrees with net income to common shareholders over basic shares within 2%, so it is shown instead.
FY16 – FY20 · 5 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-04-01 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Scinai Immunotherapeutics' revenue last fiscal year?

Scinai Immunotherapeutics reported revenue of $1,311.0K in fiscal 2025, up 99.2% from fiscal 2024.

What was Scinai Immunotherapeutics' net income?

Scinai Immunotherapeutics reported net income of −$8,307.0K in fiscal 2025, a net margin of −633.6%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.